Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy

Francesco Paolo Tambaro; Sajad Khazal; Cesar Nunez; Dristhi Ragoonanan; Priti Tewari; Demetrios Petropoulos; Partow Kebriaei; William George Wierda; Kris Michael Mahadeo

doi:10.1002/ccr3.2918

Clinical Case Reports (Sep 2020)

Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy

Francesco Paolo Tambaro,
Sajad Khazal,
Cesar Nunez,
Dristhi Ragoonanan,
Priti Tewari,
Demetrios Petropoulos,
Partow Kebriaei,
William George Wierda,
Kris Michael Mahadeo

Affiliations

Francesco Paolo Tambaro: Department of Pediatrics Pediatric Stem Cell Transplantation and Cellular Therapy CARTOX Program The University of Texas MD Anderson Cancer CenterChildren's Cancer Hospital Houston TexasUSA
Sajad Khazal: Department of Pediatrics Pediatric Stem Cell Transplantation and Cellular Therapy CARTOX Program The University of Texas MD Anderson Cancer CenterChildren's Cancer Hospital Houston TexasUSA
Cesar Nunez: Department of Pediatrics The University of Texas MD Anderson Cancer CenterChildren's Cancer Hospital Houston TexasUSA
Dristhi Ragoonanan: Department of Pediatrics The University of Texas MD Anderson Cancer CenterChildren's Cancer Hospital Houston TexasUSA
Priti Tewari: Department of Pediatrics Pediatric Stem Cell Transplantation and Cellular Therapy CARTOX Program The University of Texas MD Anderson Cancer CenterChildren's Cancer Hospital Houston TexasUSA
Demetrios Petropoulos: Department of Pediatrics Pediatric Stem Cell Transplantation and Cellular Therapy CARTOX Program The University of Texas MD Anderson Cancer CenterChildren's Cancer Hospital Houston TexasUSA
Partow Kebriaei: Department of Stem Cell Transplantation and Cellular Therapy CARTOX Program The University of Texas MD Anderson Cancer Center Houston TexasUSA
William George Wierda: Department of Leukemia The University of Texas MD Anderson Cancer Center Houston TexasUSA
Kris Michael Mahadeo: Department of Pediatrics Pediatric Stem Cell Transplantation and Cellular Therapy CARTOX Program The University of Texas MD Anderson Cancer CenterChildren's Cancer Hospital Houston TexasUSA

DOI: https://doi.org/10.1002/ccr3.2918
Journal volume & issue: Vol. 8, no. 9
pp. 1678 – 1681

Abstract

Read online

Abstract The T‐cell engager monoclonal antibody, blinatumomab, is a potential therapeutic strategy for refractory B acute lymphoblastic leukemia after failure of CD 19 chimeric antigen receptor T‐cell therapy.

Published in Clinical Case Reports

ISSN: 2050-0904 (Online)
Publisher: Wiley
Country of publisher: United Kingdom
LCC subjects: Medicine: Medicine (General)
Website: https://onlinelibrary.wiley.com/journal/20500904

About the journal

Abstract

Keywords